Uttar Pradesh Journal of Zoology

Volume 45, Issue 13, Page 170-188, 2024; Article no.UPJOZ.3557
ISSN: 0256-971X (P)

Unveiling the Ocean's Arsenal: Successful Integration of Marine Metabolites into Disease Management

Ajit Pal Singh [a++*], Rahul Saxena [b#], Suyash Saxena [b++] and Neelesh Kumar Maurya [c++]

[a] Department of Medical Lab Technology, SSAHS, Sharda University, Gr. Noida, U.P, India.
[b] Department of Biochemistry, SSAHS, Sharda University, Gr. Noida, U.P, India.
[c] Department of Nutrition and Dietetics, SSAHS, Sharda University, Gr. Noida, U.P, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: https://doi.org/10.56557/upjoz/2024/v45i134146

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://prh.mbimph.com/review-history/3557

Review Article

Received: 20/03/2024
Accepted: 26/05/2024
Published: 10/06/2024

ABSTRACT

The growing problem of antibiotic resistance calls for a paradigm shift in medication discovery. Fortunately, the enormous oceans, home to an incredible diversity of life, provide a viable solution: marine metabolites. These unusual chemicals have enormous potential for treating a wide range of diseases. This present study investigates the great potential for using these marine-derived gems in disease management techniques. Despite the difficulty of procuring and isolating marine organisms, discovering the most effective metabolites, and traversing lengthy research pipelines, the potential rewards are apparent. To demonstrate the power of these marine resources, the paper examines successful case studies. Each case study delves deeply into a single marine metabolite, including

[++] Assistant Professor;
[#] Professor;
**Corresponding author: Email: ajit.singh1@sharda.ac.in;*

Cite as: *Singh, Ajit Pal, Rahul Saxena, Suyash Saxena, and Neelesh Kumar Maurya. 2024. "Unveiling the Ocean's Arsenal: Successful Integration of Marine Metabolites into Disease Management". UTTAR PRADESH JOURNAL OF ZOOLOGY 45 (13):170-88. https://doi.org/10.56557/upjoz/2024/v45i134146.*

its source organism, the disease it targets, and the precise mechanism by which the metabolite disrupts the disease process. We'll look at the results of clinical trials that examined the efficacy and safety of these marine-derived medications, eventually exposing the real-world influence on patient outcomes after incorporating them into treatment plans. Examining these successful cases provides useful insights into the enormous potential of marine resources for producing novel and effective medications, opening the path for further discovery and innovation in the battle against a wide range of diseases.

Keywords: Antibiotic; marine; drug; study; organism; disease.

1. INTRODUCTION

The once-miraculous power of antibiotics to vanquish a vast array of infectious diseases now faces a formidable challenge the persistent rise of antimicrobial resistance (AMR). The indiscriminate use and overuse of antibiotics in human medicine, agriculture, and aquaculture has exerted a persistent selection pressure on microbial populations, favouring the emergence of resistant strains [1,2]. Tetracyclines, β-lactams antibiotics, aminoglycosides, and sulphonamides are extensively used antibiotic in agriculture and has become global concern for scientific community.These multidrug-resistant (MDR) pathogens are not only impervious to conventional antibiotics but can also readily disseminate resistance genes to other bacteria, creating a nightmarish scenario where even minor infections become potentially life-threatening. This public health crisis threatens to plunge modern medicine back into a pre-antibiotic era, jeopardizing the success of lifesaving surgeries, cancer treatments, and other medical interventions that rely on effective antibiotic prophylaxis. The spectre of a post-antibiotic world looms large, demanding a paradigm shift in our approach to infectious diseases.In this critical juncture, the scientific community is compelled to explore alternative therapeutic strategies [3,4]. Fortunately, a vast and largely untapped reservoir of potential solutions lies beneath the waves: the ocean. Encompassing a staggering diversity of life forms, from microscopic plankton to majestic whales, the marine environment represents a treasure trove of unique and potentially life-saving biomolecules. Marine organisms have evolved over millennia in a dynamic and often harsh environment, constantly adapting to survive and thrive. This evolutionary pressure has driven the production of a remarkable array of secondary metabolites, complex organic compounds not directly involved in growth and reproduction. These marine natural products exhibit a breath-taking spectrum of biological activities, including potent antimicrobial, anti-inflammatory,anticancer,and immunomodulatory properties [5,6]. The structural diversity of these marine metabolites often surpasses that of terrestrial natural products, offering a distinct advantage in drug discovery. They possess novel mechanisms of action, potentially bypassing the resistance pathways developed by bacteria against existing antibiotics. This untapped potential for novel drug discovery has ignited a surge of scientific interest in harnessing the power of the marine biosphere for the development of next-generation therapeutics. However, successfully integrating these marine metabolites into established disease management protocols presents a complex and multifaceted challenge. The vast expanse of the oceans makes exploration and collection of marine organisms a daunting task. Extracting and isolating the desired metabolites from often minute quantities of biological material requires innovative techniques and sophisticated instrumentation. Furthermore, rigorous characterization of these complex molecules is essential to elucidate their structure, function, and potential toxicity [7]. Preclinical evaluation, involving rigorous in vitro and in vivo studies, is crucial to establish the efficacy and safety of promising marine natural products. Unfortunately, the high attrition rate during drug development, coupled with the significant financial investment required, often discourages pharmaceutical companies from pursuing these potentially ground-breaking marine-derived drugs. Despite these hurdles, there have been significant advancements in recent years. Technological breakthroughs in marine exploration, bioprospecting, and natural product chemistry have facilitated the discovery and characterization of novel marine metabolites with promising therapeutic potential. Collaborative efforts between academia, government agencies, and the pharmaceutical industry are fostering a more streamlined approach to marine drug discovery and development. By critically analysing the successes and failures of past.

Table 1. A descriptive of clinical trials and development

Stage	Focus for Marine Metabolites	Challenges	Success Metrics	Examples
Preclinical Research	***In vitro* Studies:** Evaluate activity against disease targets (e.g., cancer cells, bacteria). ***In vivo* Studies:** Assess efficacy and safety in marine organism models or relevant animal models (considering potential bioaccumulation and environmental impact).	Isolating and purifying sufficient quantities of the metabolite. Identifying the metabolite's mechanism of action. Ensuring the metabolite can be delivered effectively (orally, topically, etc.).	Demonstration of targeted activity against disease processes. Favourable safety profile in animal models. Identification of an appropriate dosage range for human trials.	Ziconotide (derived from cone snails) for chronic pain: Demonstrated potent pain relief in cell cultures and showed efficacy in reducing pain in rats.
Phase I	Evaluate safety and tolerability in healthy volunteers. Assess potential for bioaccumulation and marine-specific side effects. Determine appropriate dosing for further trials considering metabolite stability and absorption.	Difficulty obtaining sufficient quantities of the purified metabolite for human trials. Potential for unexpected side effects due to the novel nature of marine compounds.	No serious adverse events observed. Identification of a safe dosage range for further testing.	Eribulin mesylate (derived from a marine sponge) for metastatic breast cancer: Phase I trials showed good tolerability and determined a safe dosage range for Phase II trials.
Phase II	Evaluate efficacy against the target disease in a small group of patients. Refine dosage and treatment schedule based on metabolite pharmacokinetics (movement through the body). Monitor for uncommon side effects specific to the marine metabolite.	Limited availability of the marine metabolite may restrict patient enrollment. The disease may require longer treatment periods than the trial duration, making efficacy assessment challenging.	Demonstration of clinical activity against the disease. Identification of an effective dosage and treatment schedule.	Aplidin (derived from a sea squirt) for acute myeloid leukemia: Phase II trials showed promising anti-leukemia activity and established a well-tolerated dose.
Phase III	Conduct large-scale, randomized controlled trials comparing the marine metabolite to existing treatments or placebo. Evaluate long-term safety and efficacy of the marine metabolite.	Large-scale production and purification of the marine metabolite may be costly and time-consuming. Recruiting a large enough patient population can be challenging.	Confirmation of clinical benefit compared to existing treatments. Favourable long-term safety profile.	E7389 (derived from a deep-sea bacterium) for cystic fibrosis: Phase III trials demonstrated improved lung function compared to placebo and confirmed safety for long-term use.

endeavours, we can pave the way for the seamless integration of marine metabolites into the clinical armamentarium. This dissertation aims to delve into these exciting yet challenging aspects of marine drug discovery, exploring the scientific advancements, the challenges encountered, and the future directions in this burgeoning field. By harnessing the immense potential of the marine biosphere, we can usher in a new era of effective and sustainable disease management, safeguarding public health and ensuring a future where infectious diseases are not an insurmountable threat.

The human narrative with the ocean has always been one of awe and trepidation. Its vastness holds a captivating mystery, a hidden world teeming with life unlike anything found on land. While we have long utilized the ocean's bounty for food and resources, a more recent scientific exploration is revealing its immense potential as a pharmacy of the future. The rise of antibiotic resistance, a spectre haunting modern medicine, has ignited a renewed interest in this aquatic frontier [8]. Antioxidants play a crucial role in the later stages of cancer progression as oxidative processes boost carcinogenesis. Many marine herbs and spices have antioxidant property including's white pepper, rosemary, thyme, pepperand ginger [9]. Marine organisms, through millennia of evolution in a dynamic and often hostile environment, have developed a remarkable arsenal of unique and therapeutically valuable metabolites. These secondary metabolites, complex organic compounds not directly involved in growth or reproduction, offer a breath-taking array of biological activities with the potential to revolutionize disease management [10]. The vast potential of marine organisms as a source of novel drugs stems from their unique evolutionary pressures. Unlike terrestrial organisms, marine life has adapted to an environment with extremes of pressure, temperature, salinity, and sunlight penetration. This constant struggle for survival has driven the production of structurally diverse and often complex metabolites, many with potent biological activities. These marine natural products exhibit a remarkable range of properties, including antimicrobial, anti-inflammatory, anticancer and neuroprotective property [11].

Antimicrobial Activity: Marine organisms, constantly battling a diverse array of microbial competitors, have evolved a sophisticated chemical defence system. Antimicrobial peptides, halogenated compounds, and polysaccharides isolated from marine invertebrates, algae, and bacteria have shown promising activity against a broad spectrum of bacteria, fungi, and viruses, including multidrug-resistant (MDR) strains. Red algae have lectin compound which have antiviral activity against various type of virus including HIV, hepatitis, influenza, encephalitis, coronavirus and herpes simplex virus [12].

Anti-inflammatory and Immunomodulatory Activity: Marine organisms possess a complex interplay with their surrounding environment, often relying on intricate immune responses to combat infections and environmental insults. Extracts from sponges, sea cucumbers, and marine algae have demonstrated potent anti-inflammatory and immunomodulatory properties, offering potential therapeutic avenues for chronic inflammatory diseases like arthritis and autoimmune disorders [13].

Anticancer Activity: The harsh marine environment can be a breeding ground for mutations, necessitating robust defence mechanisms in marine organisms. Compounds isolated from sponges, ascidians, and marine cyanobacteria have exhibited significant anti proliferative and cytotoxic effects against various cancer cell lines, suggesting potential for novel cancer therapies. Anticancer compounds from seaweeds can promote cancer cell death via diverse mechanism. Fucoidan extracted from seaweed inhibit cancerous activity via anti-angiogenesis as a result cell become oxygen deficient and undergo cell death [14].

Neuroprotective Activity: Marine organisms have adapted to navigate the vast ocean depths, often relying on sophisticated sensory and nervous systems. Compounds isolated from marine fish, algae, and invertebrates have displayed neuroprotective properties, offering potential avenues for the treatment of neurodegenerative diseases like Alzheimer's and Parkinson's [15].

Algal metabolites, such as fucoxanthin, fucosterol, and fucoidan might be potential leads for the development of neuroprotective therapy against brain diseases.

The structural diversity of these marine metabolites often surpasses that of terrestrial natural products. This complexity can translate into novel mechanisms of action, potentially bypassing the resistance pathways developed by pathogens against existing drugs. Marine natural

products offer a distinct advantage in drug discovery, as they are often not subject to the same selective pressures that have driven the emergence of resistance in terrestrial organisms.Furthermore, the sheer diversity of marine life suggests an untapped reservoir of potential drugs waiting to be discovered [16]. Marine environments encompass a staggering array of life forms, from microscopic plankton to giant whales, each with unique metabolic pathways and potentially novel bioactive compounds. North Atlantic right whales (*Eubalaena glacialis*), release ammonium and phosphate (NH4+, PO43-) in fecal plumes which is good source of nutrition for phytoplankton. Estimates suggest that less than 10% of marine species have been taxonomically classified, highlighting the vast potential for future discoveries.However, unlocking the therapeutic potential of marine metabolites requires overcoming significant challenges [17]. The vastness of the oceans makes exploration and collection of marine organisms a daunting task. Innovative techniques and sophisticated instrumentation are needed to efficiently extract and isolate the desired metabolites from often minute quantities of biological material. Furthermore, rigorous characterization of these complex molecules is essential to elucidate their structure, function, and potential toxicity. Preclinical evaluation, involving rigorous in vitro and in vivo studies, is crucial to establish the efficacy and safety of promising marine natural products [18]. Despite these hurdles, the potential rewards are immense. Marine drug discovery has already yielded several successful examples, with drugs derived from marine sources used for the treatment of cancer, pain, and viral infections. Technological advancements in marine exploration, bioprospecting, and natural product chemistry are facilitating the discovery and characterization of novel marine metabolites with promising therapeutic potential such as *Sargassum fusifrome* marine algae contain polysaccharide SFP-F2. Play a crucial role in cytokine production and modulate immune response by the production via NF-κB signalling pathway [19]. Collaborative efforts between academia, government agencies, and the pharmaceutical industry are fostering a more streamlined approach to marine drug discovery and development.This dissertation delves into the exciting yet challenging world of marine drug discovery. By exploring the vast potential of marine organisms as a source of unique and therapeutically valuable metabolites, we can pave the way for the successful integration of these novel drugs into disease management protocols [20]. This journey will encompass the scientific advancements in marine natural product discovery, the challenges encountered, and the future directions in this burgeoning field. By harnessing the immense potential of the marine biosphere, we can usher in a new era of effective and sustainable disease management, safeguarding public health and ensuring a future where the ocean's bounty extends beyond food and resources to encompass a vast pharmacy for the benefit of humankind [21]. The spectre of a post-antibiotic world looms large. The rampant misuse and overuse of antibiotics in human medicine, agriculture, and aquaculture has fuelled the rise of antimicrobial resistance (AMR), rendering once-potent drugs ineffective against a growing arsenal of multidrug-resistant (MDR) pathogens. This public health crisis threatens to plunge modern medicine back into a pre-antibiotic era, jeopardizing the success of lifesaving surgeries, cancer treatments, and other medical interventions that rely on effective antibiotic prophylaxis [22]. In this critical juncture, the scientific community is compelled to explore alternative therapeutic strategies. Fortunately, the vast and largely unexplored oceans offer a glimmer of hope. Marine organisms, through millennia of evolution in a dynamic and often harsh environment, have developed a remarkable arsenal of unique and therapeutically valuable metabolites [23]. These secondary metabolites, complex organic compounds not directly involved in growth and reproduction, exhibit a breath-taking array of biological activities, including potent antimicrobial, anti-inflammatory,anticancer,and immunomodulatory properties. However, the journey from the ocean depths to the bedside table is a complex and multifaceted one. This dissertation delves into the exciting concept of integrating these marine metabolites into established disease management protocols, exploring the scientific advancements, the challenges encountered, and the future directions in this burgeoning field [24].

The successful integration of marine metabolites hinges on a multi-pronged approach. Here, we will explore the key steps involved:

Bioprospecting and Discovery: The vastness of the oceans presents a significant challenge in locating and collecting marine organisms with potential therapeutic value. Advances in marine exploration technologies, such as remotely operated vehicles (ROVs) and submersibles, are facilitating the exploration of deeper ocean



Fig. 1. Metabolomics general overview



Fig. 2. Components of cell culture media

ecosystems, previously inaccessible to traditional methods [25]. Bioprospecting, the systematic search for bioactive compounds from living organisms, plays a crucial role in identifying promising marine candidates. This involves the collection and screening of marine organisms for the presence of desired biological activities. Recent advancements in high-throughput screening (HTS) techniques have significantly accelerated the bioprospecting process, allowing for the rapid evaluation of a large number of marine samples [26].

Extraction, Isolation, and Characterization: Once a marine organism with promising bioactivity is identified, efficient extraction and isolation methods are required to obtain the desired metabolites. Depending on the source organism and the target molecule, a variety of techniques might be employed, including solvent extraction, supercritical fluid extraction, and chromatographic techniques. Following isolation, rigorous characterization of the marine metabolite is essential. This involves elucidating its structure using advanced spectroscopic

techniques such as nuclear magnetic resonance (NMR) and mass spectrometry (MS)Grosso. Understanding the structure of the metabolite is crucial for determining its mechanism of action and potential for further development into a drug [27].

Preclinical Evaluation: Once the structure and biological activity of a promising marine metabolite are established, preclinical evaluation is undertaken to assess its efficacy and safety [28]. This involves a series of in vitro and in vivo studies. In vitro studies utilize cell lines and model organisms to evaluate the direct effect of the marine metabolite on target cells and pathogens. In vivo studies, often conducted using animal models, provide crucial insights into the efficacy and potential toxicity of the metabolite in a whole organism. Preclinical evaluation plays a pivotal role in determining the viability of a marine metabolite for further development into a clinical candidate [29].

Clinical Trials and Drug Development: Marine metabolites that demonstrate promising results in preclinical evaluation can then progress to clinical trials. Clinical trials are a rigorous and carefully regulated process that involves testing the drug candidate in humans. They are typically conducted in phases, with each phase designed to assess the safety, efficacy, and dosage of the drug in an increasingly larger number of participants [30]. The success rate for new drug development is notoriously low, and marine-derived drugs face additional challenges due to the novelty of their source material. However, successful completion of clinical trials is a critical step in bringing a marine metabolite to market and integrating it into disease management protocols [31].

Regulatory Approval and Integration: Following successful clinical trials, a drug candidate derived from a marine metabolite must undergo a rigorous review process by regulatory agencies like the Food and Drug Administration (FDA) in the United States. This review process ensures that the drug meets stringent safety and efficacy standards before it can be made available for widespread use. Once approved, the marine-derived drug can be integrated into existing disease management protocols [32]. This integration involves developing guidelines for physicians on when and how to prescribe the new drug, as well as educating healthcare professionals and patients about its potential benefits and risks [33]. The successful integration of marine metabolites into disease management protocols signifies a paradigm shift in our approach to treating a wide range of diseases. It offers the potential to overcome the challenges posed by antimicrobial resistance, develop novel therapeutic options for chronic inflammatory diseases and cancers, and improve overall patient outcomes. However, significant challenges remain [34]. The high cost of marine drug discovery and development, coupled with the complex regulatory processes involved, can deter pharmaceutical companies from investing in this field furthermore.

2. CHALLENGES IN MARINE DRUG DISCOVERY

The tide is turning in the fight against infectious diseases. The once-miraculous power of antibiotics is fading as the spectre of antimicrobial resistance (AMR) rises. The relentless misuse and overuse of antibiotics in human medicine, agriculture, and aquaculture has fuelled the emergence of multidrug-resistant (MDR) pathogens, rendering many antibiotics powerless [35]. This public health crisis threatens to plunge modern medicine back into a pre-antibiotic era, jeopardizing the success of lifesaving surgeries, cancer treatments, and other medical interventions that rely on effective antibiotic prophylaxis. In this critical juncture, the scientific community is compelled to explore alternative therapeutic strategies. Fortunately, a vast and largely unexplored frontier beckons: the ocean. Marine organisms, through millennia of evolution in a dynamic and often harsh environment, have developed a remarkable arsenal of unique and therapeutically valuable metabolites [36]. These secondary metabolites, complex organic compounds not directly involved in growth and reproduction, exhibit a breath-taking array of biological activities, including potent antimicrobial, anti-inflammatory, anticancer, and immunomodulatory properties. However, the journey from the ocean depths to the medicine cabinet is fraught with challenges. This dissertation delves into the exciting yet challenging realm of marine drug discovery, with a particular focus on the hurdles that must be overcome to successfully integrate these marine metabolites into established disease management protocols [37]. While the potential of marine natural products is undeniable, translating this potential into tangible therapeutic benefits requires navigating a complex obstacle course.

2.1 Conquering the Hurdles of Marine Drug Discovery

Exploration and Collection: The vastness of the oceans presents a significant logistical challenge. Unlike terrestrial environments, readily accessible for exploration and sample collection, the ocean depths remain largely unexplored [38-41]. Remotely operated vehicles (ROVs) and submersibles offer access to deeper ecosystems, but their operation is expensive and requires specialized expertise. Additionally, many marine organisms with potential therapeutic value reside in geographically remote or environmentally sensitive locations, necessitating careful consideration of ethical and sustainable collection practices [42-46].

Bioprospecting and Target Identification: Identifying promising marine organisms with therapeutic potential requires a systematic approach known as bioprospecting. This involves collecting and screening a vast number of marine samples for the presence of desired biological activities [47-51]. While advancements in high-throughput screening (HTS) techniques have accelerated this process, it remains a time-consuming and resource-intensive endeavour. Furthermore, even after identifying a marine organism with promising bioactivity, pinpointing the specific metabolite responsible for that activity can be challenging. This necessitates sophisticated isolation and purification techniques, coupled with advanced analytical tools for structural elucidation [52-56].

Extraction and Isolation: Once a promising marine organism and its bioactive metabolite are identified, efficient and sustainable extraction methods are required. Traditional solvent extraction techniques can be harsh and may degrade delicate marine natural products [57].

Innovative approaches such as supercritical fluid extraction and biomimicry-inspired extraction methods offer promising alternatives. However, scaling up these techniques for large-scale production can be challenging, especially for marine organisms that are difficult to cultivate in captivity [58].

Characterization and Analysis: Following isolation, rigorous characterization of the marine metabolite is essential. This involves elucidating its complex structure using advanced spectroscopic techniques such as nuclear magnetic resonance (NMR) and mass spectrometry (MS). Understanding the structure of the metabolite is crucial for determining its mechanism of action and potential for further development as a drug [59-61]. However, characterizing these structurally complex marine natural products can be time-consuming and expensive, requiring specialized expertise and sophisticated instrumentation.

Preclinical Evaluation: Once the structure and biological activity of a promising marine metabolite are established, preclinical evaluation is undertaken to assess its efficacy and safety. This involves a series of in vitro and in vivo studies. In vitro studies utilize cell lines and model organisms to evaluate the direct effect of the marine metabolite on target cells and pathogens. In vivo studies, often conducted using animal models, provide crucial insights into the bioavailability, efficacy, and potential toxicity of the metabolite in a whole organism. However, ethical considerations and the inherent limitations of animal models can pose challenges in preclinical evaluation [62,63].

Drug Development and Clinical Trials: Marine metabolites that demonstrate promising results in preclinical evaluation can then progress to clinical trials. Clinical trials are a rigorous and meticulously regulated process that involves testing the drug candidate in humans [64-66]. They are typically conducted in phases, with each phase designed to assess the safety, efficacy, and dosage of the drug in an increasingly larger number of participants. The success rate for new drug development is notoriously low, with an estimated 90% of drug candidates failing to reach market. Marine-derived drugs face additional challenges due to the novelty of their source material and the potential for complex pharmacokinetics and metabolic pathways in humans [67-71].

Regulatory Approval and Cost: Following successful clinical trials, a drug candidate derived from a marine metabolite must undergo a stringent review process by regulatory agencies like the Food and Drug Administration (FDA) in the United States. This review process ensures that the drug meets stringent safety and efficacy standards before it can beimplemented [72,73].

3. CASE STUDIES

Case Study 1: The fight against cancer remains a relentless pursuit in modern medicine. Despite the development of a diverse armamentarium of

Table 2. A descriptive for challenges in marine drug discovery

Category	Challenge	Description	Impact
Sample Collection	**Remote and Harsh Environments:** Accessing deep-sea organisms or those in extreme environments requires specialized equipment and expertise, increasing costs and risks.	Difficulty acquiring sufficient quantities and diverse marine samples for exploration.	Delays discovery and limits access to potentially valuable metabolites.
Species Identification and Cultivation	**Taxonomic Uncertainties:** Many marine species are poorly understood, making identification and potential large-scale cultivation difficult.	Inability to reliably reproduce the source of bioactive compounds.	Hinders development and standardization of marine-derived drugs.
Metabolite Isolation and Characterization	**Complex Mixtures:** Marine organisms often produce a complex cocktail of compounds, requiring sophisticated techniques to isolate and purify the desired metabolite.	Difficulty identifying and characterizing the specific compound responsible for the desired biological activity.	Delays drug development and increases costs associated with purification processes.
Bioassay Development	**Target Specificity:** Developing appropriate assays to screen marine metabolites for specific disease targets can be challenging.	Difficulty identifying metabolites with therapeutic potential against specific diseases.	Limits the efficiency of drug discovery and may lead to overlooking valuable compounds.
Drug Development Costs	**Long Development Pipeline:** The entire drug development process, including clinical trials, can be lengthy and expensive.	High financial investment required to bring a marine-derived drug to market.	Discourages pharmaceutical companies from investing in marine drug discovery due to high risk-to-reward ratio.
Environmental Considerations	**Overexploitation and Sustainability:** Unsustainable harvesting practices can threaten marine ecosystems and limit the availability of marine resources.	Potential environmental damage can limit access to marine metabolites and raise ethical concerns.	Requires responsible sourcing practices and exploration of sustainable cultivation methods.

chemotherapeutic drugs, the emergence of resistance and the debilitating side effects associated with many existing treatments highlight the need for novel therapeutic strategies [74-76]. The vast and largely unexplored marine biosphere offers a glimmer of hope, harbouring a wealth of unique and potentially life-saving natural products. This section tells the story of eribulin (Halaven®), a medicine made from something found in the ocean. Eribulin is now used to fight certain types of breast cancer and a kind of cancer called liposarcoma that has spread to other parts of the body [77-81].

3.1 From Sponge to Chemotherapy: Unveiling Erbulin's Origins

The journey of eribulin began in the depths of the Pacific Ocean, with the identification of a potent antitumor compound called halichondrin B. This complex macrocyclic lactone was isolated from the marine sponge Halichondriaokadai, a colourful orange sponge found in Japanese waters. Extensive research efforts by researchers at the Japanese Pharmaceutical Company Eisai led to the development of eribulin, a synthetic derivative of halichondrin B that retains its potent antitumor activity while overcoming some of the limitations associated with the natural product [82].

3.2 Targeting Microtubules: Erbulin's Mechanism of Action

Erbulin's therapeutic prowess lies in its unique mechanism of action. Cancer cells are characterized by uncontrolled and rapid proliferation. This rapid growth relies heavily on the proper functioning of microtubules, a network of protein filaments that play a crucial role in cell division. Erbulin disrupts microtubule dynamics by binding to a specific site on the β-tubulin subunit, a building block of microtubules [83]. This binding prevents the proper assembly and disassembly of microtubules, leading to cell cycle arrest and ultimately, programmed cell death (apoptosis) in cancer cells.

3.3 Clinical Trials and the Path to Approval

Eribulin's promising preclinical results paved the way for a series of rigorous clinical trials to evaluate its efficacy and safety in humans. In a pivotal Phase III clinical trial involving over 1,100 patients with metastatic breast cancer who had progressed after receiving prior chemotherapy, eribulin demonstrated significant improvement in overall survival compared to the standard treatment, an anthracycline-based chemotherapy regimen. The study revealed a median overall survival of 13.1 months for patients treated with eribulincompared to 10.6 months for those receiving the standard therapy [84]. Additionally, eribulin exhibited a more favourable side effect profile, with less severe neutropenia (low white blood cell count) and neuropathy (nerve damage) compared to the standard chemotherapy. Following this success, eribulin received approval from the Food and Drug Administration (FDA) in 2010 for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for advanced or metastatic disease (http://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2010/201532lbl.Pdf.). In 2016, eribulin's approval was further expanded to include the treatment of patients with advanced liposarcoma, a rare and aggressive form of soft tissue cancer. Clinical trials demonstrated that eribulin improved progression-free survival (the time a patient life without their cancer worsening) compared to a placebo in patients with advanced liposarcoma who had not responded to prior chemotherapy [85].

Table 3. A descriptive of Erbulin's mechanism of action

Aspect	Description
Target	Microtubules (cellular scaffold components)
Action	**Primarily:** Inhibits microtubule depolymerisation (breakdown) **Secondarily:** May promote microtubule catastrophe (sudden disassembly) at high concentrations
Binding Site	Specific site on the β-tubulin subunit at the growing end of microtubules
Cellular Effect	1. Disrupts cell division (mitosis) by preventing spindle formation 2. Triggers cell death (apoptosis) through prolonged mitotic arrest
Additional Effects	1. May reverse epithelial-mesenchymal transition (EMT), a process promoting cancer cell spread 2. May influence tumour microenvironment by improving blood vessel function

3.4 A Brighter Future for Cancer Management

The integration of eribulin into disease management protocols for metastatic breast cancer and advanced liposarcoma marks a significant advancement in the fight against these challenging malignancies. Erbulin offers several advantages over traditional chemotherapeutic drugs:

Novel Mechanism of Action: By targeting a distinct cellular pathway, eribulin can bypass resistance mechanisms developed by cancer cells against other chemotherapy drugs.
Improved Efficacy: Clinical trials have shown that eribulin can extend overall survival and progression-free survival in patients with advanced cancers.

Favourable Side Effect Profile: Eribulin exhibits a less severe side-effect profile compared to many traditional chemotherapeutic drugs, improving patient quality of life during treatment.The story of eribulin serves as a powerful testament to the potential of the marine biosphere for yielding novel and effective cancer therapies [86]. As research delves deeper into the ocean's vast chemical library, we can anticipate the discovery and development of more marine-derived drugs that will improve disease management and patient outcomes across a broader spectrum of illnesses. However, significant challenges remain in the exploration, discovery, and development of marine-derived drugs. The following sections will explore these hurdles and the future directions in harnessing the immense potential of the ocean's bounty for the benefit of human health [87].

Case Study 2 Chronic pain, a debilitating condition affecting millions worldwide, significantly reduces quality of life and imposes a substantial burden on healthcare systems. Traditional pain medications, such as opioids, often come with undesirable side effects, including addiction and tolerance. This ongoing struggle for effective and targeted pain management has led researchers to explore alternative avenues, with the ocean once again emerging as a potential source of relief. Ziconotide (Prialt®), a synthetic peptide derived from the venom of a cone snail, exemplifies the successful integration of a marine metabolite into a disease management protocol for chronic pain [88].

3.5 A Venomous Inspiration: Unveiling Ziconotide's Origins

The story of ziconotide begins in the warm waters of the Indo-Pacific region, with the predatory cone snail Conus magus. This brightly coloured marine snail possesses a sophisticated venom apparatus, delivering a potent cocktail of toxins to paralyze its prey. Scientists, intrigued by the cone snail's venom composition, isolated a specific peptide, ω-conotoxin MVII, which exhibited a unique effect on the nervous system. Extensive research efforts by researchers at MGI Pharma, Inc. focused on unlocking the therapeutic potential of this venom peptide [89]. Through innovative protein chemistry techniques, they synthesized a modified version of the conotoxin, ziconotide, retaining its pain-relieving properties while minimizing potential side effects.

3.6 Targeting N-Type Calcium Channels: Ziconotide's Mechanism of Action

Chronic pain often arises from the abnormal transmission of pain signals along nerve fibres. Ziconotide's therapeutic action lies in its ability to specifically target N-type calcium channels in the central nervous system, particularly within the spinal cord [90]. These channels play a crucial role in the initiation and transmission of pain signals. By selectively blocking N-type calcium channels, ziconotide disrupts the flow of calcium ions into nerve cells, effectively inhibiting the transmission of pain signals to the brain. This targeted action allows for pain relief without affecting other types of nerve function, offering a distinct advantage over traditional pain medications that often have widespread effects [91].

3.7 A New Weapon in the Fight Against Chronic Pain

The integration of ziconotide into chronic pain management protocols represents a breakthrough for patients suffering from debilitating and often intractable pain. Ziconotide offers several advantages over traditional pain medications:

Targeted Action: Ziconotide specifically blocks N-type calcium channels, leading to pain relief without affecting other neurological functions.

Reduced Risk of Addiction: Unlike opioids, ziconotide does not carry the risk of addiction or

tolerance development, offering a safer alternative for long-term pain management.

Improved Quality of Life: Ziconotide's targeted pain relief can significantly improve a patient's quality of life by allowing them to participate in daily activities with less pain and discomfort. The story of ziconotide highlights the immense potential of marine venom as a source of novel therapeutic agents [92]. Marine organisms, through their evolutionary adaptations, have developed a diverse arsenal of toxins that can be repurposed for therapeutic benefit. As research delves deeper into the chemical composition of marine venoms, we can anticipate the discovery of more targeted and effective pain management strategies, offering hope to millions struggling with chronic pain. However, the successful integration of marine metabolites into disease management protocols faces numerous challenges, including exploration and collection difficulties, complex drug development processes, and high associated costs [93]. The following sections will explore these hurdles and discuss future directions in harnessing the immense potential of the marine biosphere for human health.

4. OVERCOMING CHALLENGES AND FUTURE DIRECTIONS

Despite the promise held by marine metabolites, translating this potential into tangible therapeutic benefits necessitates navigating a complex obstacle course. Here, we delve into the key challenges encountered in marine drug discovery and explore promising avenues for overcoming them:

Exploration and Collection: The vastness of the oceans presents a significant logistical hurdle. Unlike readily accessible terrestrial environments, the ocean depths remain largely unexplored. Remotely operated vehicles (ROVs) and submersibles offer access to deeper ecosystems, but their operation is expensive and requires specialized expertise. Furthermore, ethical considerations necessitate sustainable collection practices, particularly for organisms residing in vulnerable ecosystems. Collaborative efforts between marine biologists, ecologists, and drug discovery teams are crucial to ensure responsible exploration and collection of marine resources [94]. Additionally, advancements in underwater robotic technologies and the development of innovative sampling methods hold promise for facilitating efficient and sustainable collection from previously inaccessible depths.

Bioprospecting and Target Identification: Identifying promising marine organisms with therapeutic potential requires a systematic approach known as bioprospecting. This involves collecting and screening a vast number of marine samples for the presence of desired biological activities. While advancements in high-throughput screening (HTS) techniques have accelerated this process, it remains a time-consuming and resource-intensive endeavour [95]. Recent advancements in artificial intelligence (AI) and machine learning offer exciting possibilities for streamlining bioprospecting efforts. By analysing vast datasets of marine organism properties and biological activities, AI algorithms can potentially predict the presence of specific metabolites with desired therapeutic effects. This data-driven approach can significantly reduce the time and resources required to identify promising candidates for further investigation.

Extraction and Isolation: Once a promising marine organism and its bioactive metabolite are identified, efficient and sustainable extraction methods are required. Traditional solvent extraction techniques can be harsh and may degrade delicate marine natural products. Innovative approaches such as supercritical fluid extraction and biomimicry-inspired extraction methods offer promising alternatives [96]. Furthermore, research into culturing marine organisms in controlled environments can facilitate large-scale production of valuable metabolites, circumventing the challenges associated with collection from the wild. Additionally, the development of microfluidic technologies holds promise for miniaturized and automated extraction processes, offering greater efficiency and reduced environmental impact.

Characterization and Analysis: Following isolation, rigorous characterization of the marine metabolite is essential. This involves elucidating its complex structure using advanced spectroscopic techniques such as nuclear magnetic resonance (NMR) and mass spectrometry (MS). Understanding the structure of the metabolite is crucial for determining its mechanism of action and potential for further development as a drug. However, these techniques require specialized expertise and sophisticated instrumentation, posing a significant challenge for many research

institutions. Collaborative efforts between academic institutions, pharmaceutical companies, and analytical service providers can facilitate access to these advanced technologies, accelerating the characterization of promising marine metabolites [97].

Preclinical Evaluation: Once the structure and biological activity of a promising marine metabolite are established, preclinical evaluation is undertaken to assess its efficacy and safety. This involves a series of in vitro and in vivo studies. Ethical considerations and the inherent limitations of animal models necessitate the development of more sophisticated in vitro models that can accurately predict a metabolite's behaviour in humans [98]. Additionally, the exploration of micro dosing studies in human volunteers during early clinical trials holds promise for obtaining crucial safety data while minimizing potential risks to participants.

Drug Development and Clinical Trials: Marine metabolites face additional challenges during drug development due to the novelty of their source material and the potential for complex pharmacokinetics and metabolic pathways in humans [99]. Furthermore, the high costs associated with clinical trials and the lengthy regulatory approval process can deter pharmaceutical companies from investing in marine drug discovery. To address these challenges, innovative financing models such as public-private partnerships and venture capital funding can provide the necessary resources to support the development of promising marine-derived drugs. Additionally, streamlining regulatory pathways specifically for marine-derived drug candidates, while maintaining stringent safety standards, can expedite the process of bringing these novel therapies to patients [100]. By overcoming these challenges and fostering a collaborative spirit between diverse scientific disciplines, the future of marine drug discovery appears bright. As we continue to explore the vast and largely untapped potential of the marine biosphere, we can unlock a new wave of therapeutic agents to combat a wide range of diseases, offering hope for improved health outcomes and a brighter future for generations to come [101].

5. CONCLUSION

The vast expanse of the ocean, a captivating enigma for millennia, harbours a vibrant tapestry of life unlike anything found on land. While we have long utilized the ocean's bounty for sustenance and exploration, a recent scientific awakening is revealing its immense potential as a pharmacy of the future. The spectre of antimicrobial resistance, a growing threat to modern medicine, has reignited our interest in this aquatic frontier. Marine organisms, sculpted by eons of evolution in a dynamic and often harsh environment, have developed a remarkable arsenal of unique and therapeutically valuable metabolites. These secondary metabolites, distinct from those essential for growth and reproduction, present a breath-taking array of biological activities, holding the potential to revolutionize disease management. From extending survival rates in metastatic cancers (eribulin) to offering targeted pain relief for chronic conditions (ziconotide), the successful integration of marine metabolites into established disease management protocols exemplifies their transformative impact. However, the path from the ocean depths to the medicine cabinet is not without its challenges. The vastness of the ocean necessitates advanced technologies like ROVs and submersibles for deep-sea exploration, while sustainable collection practices require collaboration between diverse scientific disciplines. Bioprospecting, the process of identifying promising marine organisms, remains time-consuming, but advancements in high-throughput screening and the integration of artificial intelligence offer exciting possibilities for streamlining the process. Despite these challenges, the future of marine drug discovery brims with promise. Advancements in technology like deep-sea robotics and novel sampling methods, coupled with the exploration of microbial diversity in extreme marine environments, hold the potential to unlock a wealth of new and undiscovered marine metabolites. Additionally, the fields of marinemetagenomics and synthetic biology provide avenues for targeted bioprospecting and manipulation of genetic pathways within marine organisms, respectively. The successful integration of marine metabolites signifies a paradigm shift in our approach to treating a wide range of illnesses. This integration offers the potential to combat antimicrobial resistance with novel mechanisms of action, develop novel cancer therapies with unique antitumor properties, manage chronic diseases with anti-inflammatory and immunomodulatory properties, and address unmet medical needs with a vast diversity of therapeutic possibilities. The progress made in integrating these compounds into clinical practice serves as a testament to the immense

potential of the ocean as a source of revolutionary drugs. As we continue to explore the ocean's depths with cutting-edge technologies and foster collaborations across scientific disciplines, the future of marine drug discovery appears bright. By harnessing the ocean's bounty, we can unlock a new wave of therapeutic agents, ushering in a brighter future for human health and well-being. The ocean's depths, once a realm of mystery, are now poised to become a wellspring of hope in the ongoing fight against disease.

ACKNOWLEDGEMENT

This project would not have been possible without the extraordinary assistance of Mrs. Seema Shairley Kumar, Administrative Officer, DMS, Ministry of Agriculture, New Delhi, India. Her moral support, guidance, and encouragement have been important in structuring the research and offering valuable comments. We are really appreciative of her willingness to share her knowledge and time.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Muthu CM, Vickram AS, Sowndharya BB, Saravanan A, Kamalesh R, DinakarkumarY. A comprehensive review on the utilization of probiotics in aquaculture towards sustainable shrimp farming. Fish & Shellfish Immunology. 2024;109459.
2. Costanzo M, De Giglio MAR, Gilhen-Baker M, Roviello GN. The chemical basis of seawater therapies: A review. Environmental Chemistry Letters. 2024;1-17.
3. Selvam J, Mal J, Singh S, Yadav A, Giri BS, Pandey A, Sinha, R. Bioprospecting marine microalgae as sustainable bio-factories for value-added compounds. Algal Research. 2024;103444.
4. Yong WTL, Thien VY, Misson M, Chin GJWL, Hussin SNIS, Chong HLH, et al. Seaweed: A bioindustrial game-changer for the green revolution. Biomass and Bioenergy. 2024;183:107122.
5. Azizan A, Venter L, Alfaro AC. Biomarkers of mussel exposure to Vibrionaceae: A review. Aquaculture International. 2024;1-33.
6. Zhang B, Jia C, Li M, Wang K, Chen J, Zhao J. Multiomics integration for the function of bacterial outer membrane vesicles in the larval settlement of marine sponges. Frontiers in Microbiology. 2024;15:1268813.
7. Wagey BT, Gunawan WB, Lasabuda R, Mayulu N, Al Mahira MFN, Lailossa DG, et al. New insight on antioxidants and anti-obesity properties of two seagrasses *Thalassiahemprichii* and *Zostera marina*: An integrated molecular docking simulation with in vitro study. F1000Research.
8. Cotas J, Lomartire S, Gonçalves AM, Pereira L. From Ocean to Medicine: Harnessing Seaweed's Potential for Drug Development. International Journal of Molecular Sciences. 2024;25(2):797.
9. Nurkolis F, Subali D, Taslim NA, Mayulu N, Hardinsyah H, Tjandrawinata RR, Kim B. Unleashing the Potential of Marine Algae in Cancer Prevention and Treatment Through Combination of Tradition and Innovation; 2024.
10. Ghallab DS, Ibrahim RS, Mohyeldin MM, Shawky E. Marine algae: A treasure trove of bioactive anti-inflammatory compounds. Marine Pollution Bulletin. 2024;199: 116023.
11. Filippou C, Themistocleous SC, Marangos G, Panayiotou Y, Fyrilla M, Kousparou CA, et al. Microbial Therapy and Breast Cancer Management: Exploring Mechanisms, Clinical Efficacy, and Integration within the One Health Approach. International Journal of Molecular Sciences. 2024; 25(2):1110.
12. Azizan A, Venter L, Zhang J, Young T, Ericson JA, Delorme NJ, et al. Interactive effects of elevated temperature and Photobacterium swingsii infection on the survival and immune response of marine mussels (*Perna canaliculus*): A summer mortality scenario. Marine Environmental Research. 2024;196:106392.
13. Pérez-Pizá MC, Sautua FJ, Szparaga A, Bohata A, Kocira S, Carmona MA. New tools for the management of fungal

pathogens in extensive cropping systems for friendly environments. Critical Reviews in Plant Sciences. 2024;43(2):63-93.
14. Chaudhary P, Janmeda P, Pareek A, Chuturgoon AA, Sharma R, Pareek A. Etiology of lung carcinoma and treatment through medicinal plants, marine plants and green synthesized nanoparticles: A comprehensive review. Biomedicine & Pharmacotherapy. 2024;173:116294.
15. Ghallab DS, Shawky E, Khalifa AA, Ibrahim RS. Insights into the molecular mechanisms of Spirulina platensis against rheumatoid arthritis through integrative serum pharmacochemistry and network pharmacology analysis. Food Bioscience. 2024;59:103902.
16. Čanak I, Kostelac D, Jakopović Ž, Markov K, Frece J. Lactic Acid Bacteria of Marine Origin as a Tool for Successful Shellfish Farming and Adaptation to Climate Change Conditions. Foods. 2024;13(7): 1042.
17. Singh AK, Srivastava RK, Pal P, Mandal S, Sahoo UK, Prakash A, et al. Microalgal biorefinery as a sustainable and cost-effective platform for co-production of high-value-added products/metabolites: An insight into emerging trends, challenges, and opportunities. Biocatalysis and Agricultural Biotechnology. 2024;103192.
18. Zhang M, Wang Y, Jiang J, Jiang Y, Song D. The Role of Catecholamines in the Pathogenesis of Diseases and the Modified Electrodes for Electrochemical Detection of Catecholamines: A Review. Critical Reviews in Analytical Chemistry. 2024;1-22.
19. Bornbusch SL, Power ML, Schulkin J, Drea CM, Maslanka MT, Muletz-Wolz CR. Integrating microbiome science and evolutionary medicine into animal health and conservation. Biological Reviews. 2024;99(2):458-477.
20. Singh AP. Importance of papanicolaou staining in gynecologic cytology. EPRA International Journal of Multidisciplinary Research (IJMR). 2022;8(9):216-219.
21. Singh AP, Batra J, Saxena S, Saxena R. A curse of Lassa fever: An update. Journal of Survey in Fisheries Sciences. 2023;1143-1150.
22. Singh AP, Saxena R, Saxena S. Plasma apheresis procedure. EPRA International Journal of Multidisciplinary Research (IJMR). 2022;8(7):205-218.
23. Pereira R, Yarish C, Critchley AT. Seaweed aquaculture for human foods in land based and IMTA systems. In Applications of Seaweeds in Food and Morin S, Atkinson PW, Walling LL. Whitefly–Plant Interactions: An Integrated Molecular Perspective. Annual Review of González-Pech RA, Li VY, Garcia V, Boville E, Mammone M, Kitano H, et al. The Evolution, Assembly, and Dynamics of Marine Holobionts. Annual Review of Marine Science. 2024;16:443-466
24. Singh AP, Saxena R, Saxena S, Batra J. An Update on Emergency Contraceptives. IJFANS. 2012;11(2):65-70.
25. Ahmad T, Kumar P, Singh AP. The Curious Case of the Sphered Blood Cells: Unveiling Hereditary Spherocytosis. Science and Technology. 2024;13(1):49-56p.
26. Yao T, Asayama Y. Animal-cell culture media: History, characteristics, and current issues. Reproductive Medicine and Biology. 2017;16(2):99-117.
27. Singh AP, Batra J, Khan SS, Saxena R, Saxena S, Singh AP, et al. Diagnosis and treatment of Wilson disease: An update. Cardiometry. 2022;2022 Dec 1(25):1397:400.
28. Ajit P, Rahul S, Suyash S. Cytopathology: An Important Aspect of Medical Diagnosis. Research & Reviews: Journal of Oncology and Hematology. 2024;12(03):13-18.
29. Singh AP, Batra J, Saxena R, Saxena S, Kumar C. Alarming rise in professional Blood donors and its repercussions. Cardiometry. 2022 Dec 1;2022(25):1394,
30. Rajaganesh R, Murugan K. Anti-dengue potential and mosquitocidal effect of marine green algae–stabilized Mn-doped superparamagnetic iron oxide nanoparticles (Mn-SPIONs): An eco- friendly approach. Environmental Science and Pollution Research. 2024;1-20.
31. Ezzouggari R, Bahhou J, Taoussi M, Seddiqi Kallali N, Aberkani K, Barka EA, Lahlali R. Yeast Warriors: Exploring the Potential of Yeasts for Sustainable Citrus Post-Harvest Disease Management. Agronomy. 2024;14(2):288.
32. Radhakrishnan DK, Akbar Ali I, Velayudhannair K, Kari ZA, Liew HJ. Exploring the role of plant oils in aquaculture practices: An overview. Aquaculture International. 2024;1-27.
33. Cordell GA. The contemporary nexus of medicines security and bioprospecting: A

future perspective for prioritizing the patient. Natural Products and Bioprospecting. 2024;14(1):1-32.
34. Kumar V, Barwal A, Sharma N, Mir DS, Kumar P, Kumar V. Therapeutic proteins: developments, progress, challenges, and future perspectives. 3 Biotech. 2024;14(4):112.
35. Püsküllüoğlu M, Michalak I. The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer. Frontiers in Pharmacology. 2024;15:1349242.
36. Muneeb M, Khan EU, Ahmad S, NaveedS, Ali M, Qazi MA, et al. An updated review on alternative strategies to antibiotics against necrotic enteritis in commercial broiler chickens. World's Poultry Science Journal. 2024;1-50.
37. Webster NS. Sponge disease: A global threat?. Environmental Microbiology. 2007; 9(6):1363-1375.
38. Zaghloul EH, El Halfawy NM, Zaghloul HA, Hassan SW, Elsayis A. Marine and Salt-TolerantPlant Growth Promoting Bioinoculants for Plant Stress Mitigation and Sustainable Agriculture. Egyptian Journal of Botany; 2024.
39. Tabassum A, Nadeem H, Azeem F, Siddique MH, Zubair M, Kanwal A, Rasul I. An integrated network pharmacology approach to discover therapeutic mechanisms of Commiphorawightii for the treatment of Bell's palsy. Journal of Biomolecular Structure and Dynamics. 2024;1-18.
40. Singh AP, Saxena RAHUL, Saxena SUYASH. A study on the working of blood bank. Journal of Medicine and Health Research. 2022;7(1):1-5.
41. Porzani SJ, Nowruzi B. Effective strategy of drug discovery from marine ecosystem. Marine Ecosystems: A Unique Source of Valuable Bioactive Compounds. 2023;3: 316-354.
42. Tan LT. Impact of marine chemical ecology research on the discovery and development of new pharmaceuticals. Marine Drugs. 2023;21(3):174.
43. Rodrigues AO, May De Mio LL, Soccol CR. Trichoderma as a powerful fungal disease control agent for a more sustainable and healthy agriculture: Recent studies and molecular insights. Planta. 2023;257(2): 31.
44. Kaidarova A, Geraldi NR, Wilson RP, Kosel J, Meekan MG, Eguíluz VM, et al. Wearable sensors for monitoring marine environments and their inhabitants. Nature Biotechnology. 2023;41(9):1208-1220.
45. Verdegem M, Buschmann AH, Latt UW, Dalsgaard AJ, Lovatelli A. The contribution of aquaculture systems to global aquaculture production. Journal of the World Aquaculture Society. 2023;54(2): 206-250.
46. Uma VS, Usmani Z, Sharma M, Diwan D, Sharma M, Guo M, et al. Valorisation of algal biomass to value-added metabolites: Emerging trends and opportunities. Phytochemistry Reviews. 2023;22(4):1015-1040.
47. Eroldoğan OT, Glencross B, Novoveska L, Gaudêncio SP, Rinkevich B, Varese GC, et al. From the sea to aquafeed: A perspective overview. Reviews in Aquaculture. 2023;15(3):1028-1057.
48. Ferrocino I, Rantsiou K, McClure R, Kostic T, de Souza RSC, Lange L, et al. The need for an integrated multi-OMICs approach in microbiome science in the food system. Comprehensive Reviews in Food Science and Food Safety. 2023;22(2):1082-1103.
49. Lahiri D, Nag M, Dey A, Sarkar T, Pati S, Nirmal NP, et al. Marine bioactive compounds as antibiofilm agent: A metabolomic approach. Archives of Microbiology. 2023;205(1):54.
50. Hong Y, Chen B, Zhai X, Qian Q, Gui R, Jiang C. Integrated analysis of the gut microbiome and metabolome in a mouse model of inflammation-induced colorectal tumors. Frontiers in Microbiology. 2023;13: 1082835.
51. Nguyen PQ, Huang X, Collins DS, Collins JJ, Lu T. Harnessing synthetic biology to enhance ocean health. Trends in Biotechnology. 2023;41(7):860-874.
52. Radjasa OK, Steven R, Humaira Z, Dwivany FM, Nugrahapraja H, Trinugroho JP, et al. Biosynthetic gene cluster profiling from North Java Sea Virgibacillussalarius reveals hidden potential metabolites. Scientific Reports. 2023;13(1):19273.
53. Omidvari M, Abbaszadeh-Dahaji P, Hatami M, Kariman K. Biocontrol: A novel eco-friendly mitigation strategy to manage plant diseases. Plant Stress Mitigators. 2023;27-56.
54. Sharma S, Shaikh S, Mohana S, Desai C, Madamwar D. Current trends in bioremediation and bio-integrated treatment of petroleum hydrocarbons.

Environmental Science and Pollution Research. 2023;1-20.

55. Amenyogbe E. Application of probiotics for sustainable and environment-friendly aquaculture management-A review. Cogent Food & Agriculture. 2023;9(1): 2226425.
56. Arriel-Elias MT, Pereira AK, Arriel GCT, Alexandre G, de Andrade Bezerra G, Fill TP, et al. Molecular networking as a tool to annotate the metabolites of Bacillus sp. and Serratia marcescens isolates and evaluate their fungicidal effects against Magnapothe oryzae and Bipolaris oryzae. 3 Biotech. 2023;13(5):148.
57. Gaudêncio SP, Bayram E, Lukić Bilela L, Cueto M, Díaz-Marrero AR, Haznedaroglu BZ, et al. Advanced methods for natural products discovery: bioactivity screening, dereplication, metabolomics profiling, genomic sequencing, databases and informatic tools, and structure elucidation. Marine Drugs. 2023;21(5):308.
58. Burlot AS, Freile-Pelegrín Y, Bourgougnon N, Pliego-Cortés H, Boulho R, Penuela A, et al. Concise review of the genus Solieria J. Agardh, 1842. Journal of Applied Phycology. 2023;35(3):961-982.
59. Ratnarajah L, Abu-Alhaija R, Atkinson A, Batten S, Bax NJ, Bernard KS, et al. Monitoring and modelling marine zooplankton in a changing climate. Nature Communications. 2023;14(1):564.
60. Cembrowska-Lech D, Krzemińska A, Miller T, Nowakowska A, Adamski C, Radaczyńska M, et al. An integrated multi-omics and artificial intelligence framework for advance plant phenotyping in horticulture. Biology. 2023;12(10):1298.
61. Corinaldesi C, Bianchelli S, Candela M, Dell'Anno A, Gambi C, Rastelli E, et al. Microbiome-assisted restoration of degraded marine habitats: A new nature-based solution?. Frontiers in Marine Science. 2023;10:1227560.
62. Thakur N, Nigam M, Mann NA, Gupta S, Hussain CM, Shukla SK, et al. Host-mediated gene engineering and microbiome-based technology optimization for sustainable agriculture and environment. Functional & Integrative Genomics. 2023;23(1):57.
63. Schwing FB. Modern technologies and integrated observing systems are instrumental to fisheries oceanography: A brief history of ocean data collection. Fisheries Oceanography. 2023;32(1): 28-69.
64. Chase AB, Bogdanov A, Demko AM, Jensen PR. Biogeographic patterns of biosynthetic potential and specialized metabolites in marine sediments. The ISME Journal. 2023;17(7):976-983.
65. Robinson NA, Robledo D, Sveen L, Daniels RR, Krasnov A, Coates A, et al. Applying genetic technologies to combat infectious diseases in aquaculture. Reviews in Aquaculture. 2023;15(2): 491- 535.
66. Akmukhanova NR, Leong YK, Seiilbek SN, Konysbay A, Zayadan BK, Sadvakasova AK, et al. Eco-friendly biopesticides derived from CO2-Fixing cyanobacteria. Environmental Research. 2023;117419.
67. Batra B, Sharma D, Bose D, Parthasarthy V, Sarkar A. Implications of bioprospecting marine diversity and sustainable production of bioactive compounds. In Marine Antioxidants. Academic Press. 2023;27-43.
68. Selvin J, Huxley AJ, Lipton AP. Immunomodulatory potential of marine secondary metabolites against bacterial diseases of shrimp. Aquaculture. 2004; 230(1-4):241-248.
69. Caesar LK, Butun FA, Robey MT, Ayon NJ, Gupta R, Dainko D, et al. Correlative metabologenomics of 110 fungi reveals metabolite–gene cluster pairs. Nature Chemical Biology. 2023;19(7):846-854.
70. Bujas T, Vladimir N, Koričan M, Vukić M, Ćatipović I, Fan A. Extended bibliometric review of technical challenges in mariculture production and research hotspot analysis. Applied Sciences. 2023; 13(11):6699.
71. Kim DY, Patel SK, Rasool K, Lone N, Bhatia K, Seth CS, Ghodake GS. Bioinspired silver nanoparticle-based nanocomposites for effective control of plant pathogens: A review. Science of the Total Environment. 2023;168318.
72. Thanigaivel S, Chandrasekaran N, Mukherjee A, Thomas J. Seaweeds as an alternative therapeutic source for aquatic disease management. Aquaculture. 2016; 464:529-536.
73. Barzkar N, Sukhikh S, Babich O, Venmathi Maran BA, Tamadoni Jahromi S. Marine collagen: purification, properties and application. Frontiers in Marine Science. 2023;10:1245077.

74. Rai S, Kaur B, Singh P, Singh A, Benjakul S, Vijay Kumar Reddy S, et al. Perspectives on phage therapy for health management in aquaculture. Aquaculture International. 2023;1-45.
75. Udayan A, Pandey AK, Sirohi R, Sreekumar N, Sang BI, Sim SJ, et al. Production of microalgae with high lipid content and their potential as sources of nutraceuticals. Phytochemistry Reviews. 2023;22(4):833-860.
76. Thukral M, Allen AE, Petras D. Progress and challenges in exploring aquatic microbial communities using non-targeted metabolomics. The ISME Journal. 2023; 17(12):2147-2159.
77. La Bianca G, Rees S, Attrill MJ, Lombard AT, McQuaid KA, Niner HJ, et al. A standardised ecosystem services framework for the deep sea. Frontiers in Marine Science. 2023;10:1176230.
78. Dang Z, Gao M, Wang L, Wu J, Guo Y, Zhu Z, et al. Synthetic bacterial therapies for intestinal diseases based on quorum-sensing circuits. Biotechnology Advances. 2023;108142.
79. Wang X, Du Z, Chen C, Guo S, Mao Q, Wu W, et al. Antifungal effects and biocontrol potential of lipopeptide-producing Streptomyces against banana Fusarium wilt fungus Fusarium oxysporum f. sp. cubense. Frontiers in Microbiology. 2023;14:1177393
80. Preston JN, Trivedi MV. Eribulin: A novel cytotoxic chemotherapy agent. Annals of Pharmacotherapy. 2012;46(6):802-811.
81. Nguyen TH, Wang SL, Nguyen VB. Microorganism-derived molecules as enzyme inhibitors to target Alzheimer's diseases pathways. Pharmaceuticals. 2023;16(4):580.
82. Rhodes LD, Parrish KL, Willis ML. Review of Best Practices for Biosecurity and Disease Management for Marine Aquaculture in US Waters; 2023.
83. Nufaisa SS, Beslin LG. Pivot Role of Bioinformatics in Drug Discovery Using Marine Natural Products as Resources; 2023.
84. Degani O, Gordani, A, Dimant, E, Chen, A, Rabinovitz, O. The cotton charcoal rot causal agent, Macrophominaphaseolina, biological and chemical control. Frontiers in Plant Science. 2023;14:1272335.
85. Singh A, Shourie A, Mazahar S. Integration of Microalgae-Based Wastewater Bioremediation–Biorefinery Process to Promote Circular Bioeconomy and Sustainability: A Review. CLEAN–Soil, Air, Water. 2023;51(3):2100407.
86. Greff B, Sáhó A, Lakatos E, Varga L. Biocontrol activity of aromatic and medicinal plants and their bioactive components against soil-borne pathogens. Plants. 2023;12(4):706.
87. Singh R, Wang Z, Marques C, Min R, Zhang B, Kumar S. Alanine aminotransferase detection using TIT assisted four tapered fiber structure-based LSPR sensor: From healthcare to marine life. Biosensors and Bioelectronics. 2023; 236:115424.
88. Young T, Gale SL, Ragg NL, Sander SG, Burritt DJ, Benedict B, et al. Metabolic Regulation of Copper Toxicity during Marine Mussel Embryogenesis. Metabolites. 2023;13(7):838.
89. Fujita R, Brittingham P, Cao L, Froehlich H, Thompson M, Voorhees T. Toward an environmentally responsible offshore aquaculture industry in the United States: ecological risks, remedies, and knowledge gaps. Marine Policy. 2023;147: 105351.
90. Segaran TC, Azra MN, Lananan F, WangY. Microbe, climate change and marine environment: Linking trends and research hotspots. Marine Environmental Research. 2023;189:106015.
91. d'Errico G, Silvia L. Novel Biological and Biotechnological Methods of Nematode Management, an Effective Strategy to Enhance Crop Productivity. In Novel Biologicaland Biotechnological Applications in Plant Nematode Management. Singapore: Springer Nature Singapore. 2023;71-93.
92. Peters MK, Astafyeva Y, Han Y, Macdonald JF, Indenbirken D, Nakel J, et al. Novel marine metalloprotease—new approaches for inhibition of biofilm formation of Stenotrophomonas maltophilia. Applied Microbiology and Biotechnology. 2023;107(23):7119-7134.
93. Parveen A, Bhatnagar P, Bisht B, Kumar S, Joshi S, Gautam P, et al. Algal nanobionics to enhance value added products–a review. Current Research in Biotechnology. 2023;5:100124.
94. Hagger JA, Jones MB, Leonard DP, Owen R, Galloway TS. Biomarkers andintegrated environmental risk assessment: Are there more questions than answers?. Integrated Environmental Assessment and

Management: An International Journal. 2006;2(4):312-329.
95. Jiang EY, Fan Y, Phung NV, Xia WY, Hu GR, Li FL. Overexpression of plastid lipid-associated protein in marinen diatom enhances the xanthophyll synthesis and storage. Frontiers in Microbiology. 2023; 14:1143017.
96. Lu T, Liu Y, Zhou L, Liao Q, Nie Y, Wang X, et al. The screening for marine fungal strains with high potential in alkaloids production by in situ colony assay and LC-MS/MS based secondary metabolic profiling. Frontiers in Microbiology. 2023;14: 1144328.
97. Kumar V, Lakkaboyana SK, Sharma N, Chakraborty P, Umesh M, Pasrija R, et al. A critical assessment of technical advances in pharmaceutical removal fromwastewater–A critical review. Case Studies in Chemical and Environmental Engineering. 2023; 100363.
98. Ma K, Liu Z, Qiao G, Ma L, Zhang F, Zhao M, et al. Effects of four diets on the metabolism of megalopa metamorphosis of the mud crab, Scylla paramamosain. Frontiers in Marine Science. 2023;10:1276717.
99. Porzani SJ, Nowruzi B. Effective strategy of drug discovery from marine ecosystem. Marine Ecosystems: A Unique Source of Valuable Bioactive Compounds. 2023;3:316-354.

Peer-review history:
The peer review history for this paper can be accessed here:
https://prh.mbimph.com/review-history/3557